Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEU-PH: JK07 in Heart Failure and Pulmonary Hypertension
NCT07221513Phase 2Withdrawn
- Sponsor
- Salubris Biotherapeutics
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Peptides, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of JK07 in heart failure (HF), pulmonary hypertension (PH), sponsored by Salubris Biotherapeutics. Planned start Dec 2025; status: withdrawn.
02
Drugs
JK07
03
Conditions
heart failure (HF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT07221513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221513.